Biomarker‐based phase I dose‐escalation, pharmacokinetic, and pharmacodynamic study of oral apricoxib in combination with erlotinib in advanced nonsmall cell …
K Reckamp, B Gitlitz, LC Chen, R Patel, G Milne… - Cancer, 2011 - Wiley Online Library
BACKGROUND: Apricoxib, a novel once‐daily selective cyclooxygenase‐2 inhibitor, was
investigated in combination with erlotinib for recurrent stage IIIB/IV nonsmall cell lung cancer …
investigated in combination with erlotinib for recurrent stage IIIB/IV nonsmall cell lung cancer …
Biomarker-based phase I dose-escalation, pharmacokinetic, and pharmacodynamic study of oral apricoxib in combination with erlotinib in advanced nonsmall cell …
K Reckamp, B Gitlitz, LC Chen, R Patel, G Milne… - Cancer, 2010 - europepmc.org
Background Apricoxib, a novel once-daily selective cyclooxygenase-2 inhibitor, was
investigated in combination with erlotinib for recurrent stage IIIB/IV nonsmall cell lung cancer …
investigated in combination with erlotinib for recurrent stage IIIB/IV nonsmall cell lung cancer …
Biomarker-based phase I dose-escalation, pharmacokinetic, and pharmacodynamic study of oral apricoxib in combination with erlotinib in advanced nonsmall cell …
K Reckamp, B Gitlitz, LC Chen, R Patel, G Milne… - Cancer, 2011 - pubmed.ncbi.nlm.nih.gov
Background Apricoxib, a novel once-daily selective cyclooxygenase-2 inhibitor, was
investigated in combination with erlotinib for recurrent stage IIIB/IV nonsmall cell lung cancer …
investigated in combination with erlotinib for recurrent stage IIIB/IV nonsmall cell lung cancer …
Biomarker‐based phase I dose‐escalation, pharmacokinetic, and pharmacodynamic study of oral apricoxib in combination with erlotinib in advanced nonsmall cell …
K Reckamp, B Gitlitz, LC Chen, R Patel, G Milne… - Cancer, 2011 - infona.pl
BACKGROUND: Apricoxib, a novel once‐daily selective cyclooxygenase‐2 inhibitor, was
investigated in combination with erlotinib for recurrent stage IIIB/IV nonsmall cell lung cancer …
investigated in combination with erlotinib for recurrent stage IIIB/IV nonsmall cell lung cancer …
[引用][C] Biomarker-Based Phase I Dose-Escalation, Pharmacokinetic, and Pharmacodynamic Study of Oral Apricoxib in Combination With Erlotinib in Advanced …
K RECKAMP, B GITLITZ, LC CHEN, R PATEL… - Cancer, 2011 - pascal-francis.inist.fr
Biomarker-Based Phase I Dose-Escalation, Pharmacokinetic, and Pharmacodynamic Study
of Oral Apricoxib in Combination With Erlotinib in Advanced Nonsmall Cell Lung Cancer …
of Oral Apricoxib in Combination With Erlotinib in Advanced Nonsmall Cell Lung Cancer …